T细胞急性淋巴细胞白血病:亚型患病率、临床结局与新兴靶向治疗
T细胞急性淋巴细胞白血病(T-ALL)约占急性白血病的20%,世界卫生组织国际共识分类仅识别早期T细胞前体ALL一个亚型。本文综述四项T-ALL基因组图谱研究,比较不同队列所报道的基因组亚型及其频率差异,总结常见基因组变异的临床结局,并提出未来研究与治疗的新方向。
要点
- T-ALL约占急性白血病的20%,属高危血液病。
- 世界卫生组织国际共识分类仅识别早期T细胞前体ALL一个亚型。
- 不同研究采用的测序与免疫表型方法不同,报道的亚型及频率存在显著差异。
核心结论
- 四项T-ALL基因组图谱研究在亚型定义上既存在共识也存在差异,常见基因组变异的临床结局受患者人口学特征和治疗方案影响。
- 本文提出未来研究与治疗的新方向。
研究设计与样本
- 综述,整合四项T-ALL基因组图谱研究的数据。
主要发现
- T-ALL约占急性白血病的20%,属高危血液病。
- 世界卫生组织国际共识分类目前仅识别早期T细胞前体ALL一个亚型。
- 各项研究采用全转录组、外显子或基因组测序以及免疫表型和细胞遗传学检测等不同方法,报道的亚型及其发生频率存在显著差异。
- 特定基因组变异的临床结局取决于患者人口学特征和治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a high-risk hematological disease constituting ~20% of acute leukemias. To date, the only subtype recognized by the World Health Organization's International Consensus Classification is early T-cell precursor ALL. To improve clinical outcomes, several studies have investigated and defined T-ALL genomic subtypes within cohorts of varied ages and geographical locations. These studies have also utilized differing analysis methods including whole transcriptome, exome, or genome sequencing as well as immunophenotyping and cytogenetic testing. As a result, there are significant differences in reported subtypes as well as the frequency at which each occurs. The reported clinical outcomes for specific genomic alterations also depend on patient demographics and treatment protocols. This review synthesizes the data from four T-ALL genomic landscape studies establishing consensus and highlighting differences, details clinical outcomes for the most common genomic alterations observed in T-ALL patients, and proposes novel avenues for future investigation and treatment.
引用
- Buckley M, Yeung DT, White DL, et al. T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments. Leukemia. 2025. PMID: 40247105. doi:10.1038/s41375-025-02599-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。